Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:23:46.229Z.
Consensus retrieved: 2026-10-06T16:34:14.101Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:23:46.229Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bc1f4c18f19876ab16fbc38bb33c2f59d02ebf5b777874ee4386cd5e587f8fe3
Forward PE Ratio (N/A) = Dated Quote Price ($7.38) / Consensus Forward EPS ($-0.94)
FORWARD PE RATIO
N/A
SOPHiA GENETICS S.A.
Market Cap
$619.15M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| SOPHiA GENETICS S.A. (SOPH) | $619.15M | N/A |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | N/A |
| OmniAb, Inc. (OABI)vs › | $630.63M | N/A |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | N/A |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 9.68 |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 2.97 |
| AngioDynamics, Inc. (ANGO)vs › | $596.01M | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.48M | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $7.38, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.94 | $-1.00 – $-0.90 | 2 | n/m |
| 2027-12-31 | $-0.63 | $-0.67 – $-0.60 | 2 | n/m |
| 2028-12-31 | $-0.36 | $-0.52 – $-0.02 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
